循环乙型肝炎病毒RNA水平在评估抗病毒治疗反应中的意义

StephenW

Current Hepatology Reports

December 2018, Volume 17, Issue 4, pp 451–458 | Cite as
Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy

    Authors
    Authors and affiliations

    Tianlun ZhouEmail authorChuanmin WangAejaz SayeedTimothy Block

    Tianlun Zhou
        1Email author
    Chuanmin Wang
        2
    Aejaz Sayeed
        1
    Timothy Block
        1

    1.Department of Translational MedicineBaruch S. Blumberg InstituteDoylestownUSA
    2.Department of Infectious DiseasesTaihe HospitalShiyanChina

Hepatitis B (J Lim, Section Editor)
First Online: 18 October 2018

    1 Shares 16 Downloads

Part of the following topical collections:

    Topical Collection on Hepatitis B

Abstract
Purpose of Review

Treatment of chronic hepatitis B infection with nucleos(t)ide analogues induces a significant inhibition of HBV DNA titer. However, reduction of viral DNA load is not an ideal marker to predict sustainable antiviral effect. Circulating HBV RNA has been, recently, explored as a novel biomarker for monitoring viral persistence and the progression of liver disease. This review aims to discuss the characteristics of circulating HBV RNA and to evaluate its applications in hepatitis B infection management.
Recent Findings

HBV RNA is readily detectable in the blood of infected patients. Circulating viral RNA is originated from polyadenylated pgRNA that is packaged in, and secreted with, either naked core particles or virion-like particles. Serum pgRNA could be presented in full length or multiple-spliced forms. The amount and composition of pgRNA in blood can be used to gauge intrahepatic cccDNA transcriptional activity, predict drug response, and reflect liver histologic changes.
Summary

Circulating HBV pgRNA is exclusively transcribed from cccDNA in the liver. As an alternative to liver biopsy, non-invasive measurement of serum HBV RNA in patients receiving antiviral treatment might provide clinicians a safe and effective tool to oversee therapeutic efficacy.
Keywords
Hepatitis B virus infection HBV biomarker cccDNA Serum pgRNA Spliced pgRNA Antiviral treatment

This article is part of the Topical Collection on Hepatitis B

齐欢畅

neilhbver

目前的肝病学报告

2018年12月，第17卷，第4期，第451-458页|引用为
循环乙型肝炎病毒RNA水平在评估抗病毒治疗反应中的意义

    作者
    作者和附属机构

    周天伦电子邮件作者川民王阿雅兹赛义德·蒂莫西座

    周天伦
        1电子邮件作者
    王传民
        2
    Aejaz Sayeed
        1
    蒂莫西布洛克
        1

    1.转化医学系Baruch S. Blumberg InstituteDoylestownUSA
    2.石河中医院感染科

乙型肝炎（J Lim，部门编辑）
首次在线：2018年10月18日

    1股16下载

以下主题集合的一部分：

    关于乙型肝炎的局部收集

抽象
审查目的

用核苷（t）ide类似物治疗慢性乙型肝炎感染诱导HBV DNA滴度的显着抑制。然而，减少病毒DNA载量并不是预测可持续抗病毒效果的理想标志物。最近，循环HBV RNA被作为监测病毒持续性和肝病进展的新型生物标志物进行了探索。本综述旨在讨论循环HBV RNA的特征，并评估其在乙型肝炎感染管理中的应用。
最近的调查结果

HBV RNA很容易在感染患者的血液中检测到。循环病毒RNA源自多腺苷酸化的pgRNA，其包装在裸核心颗粒或病毒体样颗粒中并与其分泌。血清pgRNA可以全长或多剪接的形式呈现。血液中pgRNA的量和组成可用于测量肝内cccDNA转录活性，预测药物反应，并反映肝脏组织学变化。
摘要

循环HBV pgRNA仅由肝脏中的cccDNA转录。作为肝脏活组织检查的替代方案，接受抗病毒治疗的患者血清HBV RNA的无创测量可能为临床医生提供安全有效的工具来监督治疗效果。
关键词
乙型肝炎病毒感染HBV生物标志物cccDNA血清pgRNA剪接pgRNA抗病毒治疗

本文是乙型肝炎专题收集的一部分